Skip to main content
OpenTrials
Completed

NCT Number: NCT00831090

Endothelial Function and Vein Graft Remodeling

The purpose of this study is to better understand why some vein bypass grafts develop narrowing. Evidence suggests that there is a relationship between inflammatory markers in the blood and the narrowing that occurs in blood vessels. In this study, we will look at inflammatory markers in the blood and how well the vein graft functions.

Completed

Looking for future studies?

Notify Me

Key information

Age range

22 year–89 year

Sex eligibility

All sexes

Study type

Observational

Primary location

San Francisco Veterans Affairs Medical Center, San Francisco, California, United States

Loading trial locations.

About this study

Despite the acceptance of catheter-based approaches to lower extremity reconstruction, bypass with autogenous vein remains the most durable option. In the United States alone there are approximately 100,000 lower extremity bypass procedures performed yearly. However, 30-50% of these grafts either occlude or require revision in the first 5 years.

Traditional Framingham cardiovascular risk factors such as dyslipidemia and diabetes do not predict which grafts are at risk for failure. Therefore other variables such as hemodynamic factors or endothelial function may be important in identifying vulnerable vein grafts. The applicant has previously noted that vein grafts undergo dramatic geometric remodeling within the first month after implantation into the arterial circulation. This is partly driven by hemodynamic forces such as shear stress and is thought to be related to endothelial function. Shear stress is positively correlated with early (0-1 month) luminal enlargement. This adaptive response is important to maintain bypass graft patency. However, there is considerable amount of variability in this response unaccounted for by shear stress alone. The applicant has further shown that baseline systemic inflammation dampens the ability for adequate vein graft luminal expansion and therefore may uncouple the mechano-chemical signal transduction at the endothelial level. Therefore, this study will examine the relationship between circulating levels of inflammatory mediators and endothelial function in a cohort of patients undergoing lower extremity arterial reconstruction with autogenous vein.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age > 22 or < 90 years
  • Undergoing lower extremity (infrainguinal) bypass using autologous vein for the treatment of disabling claudication or critical limb ischemia secondary to chronic atherosclerotic occlusive disease
  • Able to understand, give, and take part in the consent process

Exclusion criteria

  • Age < 22 or > 90 years
  • Grafts employing prosthetic or other non-autologous vein material in any part (e.g. composite grafts). [Patch angioplasty of inflow and outflow vessel permissible with any material]
  • Vasculitis, trauma, acute embolic disease as etiology of limb ischemia
  • History of diagnosed hypercoagulable state
  • Evidence of active infection - pneumonia, urinary tract, etc., requiring medical therapy
  • Evidence of significant local sepsis in foot or limb prior to bypass
  • Patients taking immunosuppressant medications (steroids, chemotherapeutic agents)
  • Other concurrent significant illness within 30 days
  • Non-English speakers

Treatment and study plan

Primary outcomes

  1. Successful early vein graft remodeling

    Time frame: 3 Months

    An increase in vein graft lumen diameter at three months

Sponsors and collaborators

Lead sponsor

University of California, San Francisco

Other

Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

Registry information

Acronym: EFVGR

Important dates

Study start
2009
Primary completion
2015
Study completion
2015
First posted
Jan 28, 2009
Registry last updated
Sep 23, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.